Business Wire

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

Del

Regulatory News:

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC).

These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also available free of charge, by sending a postal request to the registered offices of ERYTECH Pharma, Bâtiment Adénine, 60 Avenue Rockefeller, 69008 in Lyon (France).

About ERYTECH: www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Contact information

ERYTECH
Naomi Eichenbaum
Director Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
ERYTECH@newcap.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

9 in 10 Enterprises Report Gaps Between the Cybersecurity Culture They Have and the One They Want15.10.2018 13:35Pressemelding

With cybersecurity threats continuing to escalate worldwide, the ISACA/CMMI Institute Cybersecurity Culture Report found that just 5 percent of employees think their organization’s cybersecurity culture is as advanced as it needs to be to protect their business from internal and external threats. More than 4,800 business and technology professionals shared their insights in the global research study, conducted via online polling in June 2018. Results were released today at ISACA’s CSX North America cybersecurity conference in Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005149/en/ New global research from ISACA and the CMMI Institute shows 95% of organizations say there is a gap between the cybersecurity cultures they have and the ones they want. (Graphic: Business Wire) Cybersecurity culture is a workplace culture in which security awareness and behaviors are integrated into everyone’s daily operations, a

AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada15.10.2018 13:05Pressemelding

ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea patients reduce facial marks, wear glasses in bed and curl up closer to their bed partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005185/en/ AirFit F30 full face CPAP mask: Side View (Photo: Business Wire) Availability AirFit F30 is available for sale now in the United States and Canada, and will be on display at the Medtrade Fall conference this week in Atlanta; visit ResMed’s Booth #2116. AirFit F30 fits 93 percent of patients,1 and features a minimal-contact cushion that sits just below the nose, preventing top-of-the-nose red marks and irritation, plus reducing feelings of claustrophobia for some full face wearers. It also has ResMed’s QuietAir vent, making the mask quieter than ambient noise in the bedroom. New

Dole Launches Refreshed Brand15.10.2018 13:00Pressemelding

Dole Food Company announced today the launch of a refreshed logo and brand identity for the iconic 160-year old produce company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005069/en/ Dole strives to more thoughtfully connect and understand consumers, and their preferences and desires when it comes to shopping for fresh produce. Insights gained through this discovery process have helped influence the development decisions of this robust reimaging of the DOLE Brand. The new visual identity reflects: Dole’s values as an organization around freshness, transparency and responsibility. An evolution in the logo treatment inspired by nature and its earth-given benefits. A new visual representation of the vibrant character attributes surrounding the DOLE Brand. Refinement of true nature-based color and texture pallets and font typography. The refreshed DOLE Trademark evolves from living in the fresh air and harkens to the g

Scanlog Strengthens its Position at the Cutting Edge of Logistics Innovation by Embracing Robotic Process Automation from Softomotive15.10.2018 12:08Pressemelding

Scandinavian Logistics Partners AB (Scanlog), a rapidly expanding Scandinavian logistics company specializing in international transports, is using ProcessRobot from Softomotive to help transform its order booking process and develop a smarter workflow. ProcessRobot is a leading enterprise Robotic Process Automation (RPA) platform, including enterprise grade security and controls, with links to best-of-breed AI technologies. With ProcessRobot handling increasing numbers of customer orders, Scanlog has fortified its position as a technology leader in the logistics sector, and can deliver a speedier shipping service for its clients. Mattias Ljungberg , CEO of Scanlog, explains: “With ProcessRobot, we have reduced the time it takes to process each customer order by 89 percent. Previously it took a human employee up to four minutes to enter the booking details to our systems: now, the robot completes the task within 20 seconds.” Scanlog has ambitious plans to automate many other processes

MAXON Announces Senior Leadership Appointments15.10.2018 12:00Pressemelding

MAXON, the leading developer of professional 3D software solutions, today announced leadership appointments to make it a globally-focused software development company. The executive leadership team changes, effective immediately, reflect the strategic goals of David McGavran, Chief Executive Officer, for the future of MAXON and its acclaimed 3D software application, Cinema 4D. “This is an exciting and transformational time in the evolution of MAXON and I’m eager to work with our new leadership team that represents the very best talent across our offices poised to take MAXON to the next level,” stated McGavran. “With proven track records of delivering strong results, I am pleased to have these talented and passionate executives join me in streamlining operational initiatives to best serve global customers and partners, anticipate the ever-changing needs of the 3D digital landscape, and maintain Cinema 4D’s standing as a best-in-class market leader in 3D content creation.” Executive Team

PotNetwork Holdings, Inc. Files Form 10 To Become SEC Reporting Company15.10.2018 12:00Pressemelding

PotNetwork Holdings, Inc. (OTC Pink: POTN) announced today that it has filed a Registration Statement on Form 10 with the U.S. Securities and Exchange Commission (SEC) to register its common stock under the Securities Exchange Act of 1934, as amended (the Act) including its audited financial statements for the year ended December 31, 2017 and unaudited interim financial statements through June 30, 2018. POTN had engaged PCAOB member firm Manohar, Chowdhry & Associates, in July 2017 to replace its former auditor. The Company’s voluntary filing of the Form 10 will make the Company subject to the periodic reporting requirements of the Act which includes annual, quarterly and current report filings. Additionally, the filing will enable the Company’s management to move forward with its application to OTC Markets to uplist to the OTCQB market tier. As a result of investor feedback and management’s plan for a new, broadened strategic direction, the Company has rescinded the previously announc